PMID- 27343834
OWN - NLM
STAT- MEDLINE
DCOM- 20170313
LR  - 20170313
IS  - 1873-0329 (Electronic)
IS  - 1383-5769 (Linking)
VI  - 65
IP  - 5 Pt A
DP  - 2016 Oct
TI  - Immunogenicity and protection from malaria infection in BK-SE36 vaccinated 
      volunteers in Uganda is not influenced by HLA-DRB1 alleles.
PG  - 455-8
LID - S1383-5769(16)30076-9 [pii]
LID - 10.1016/j.parint.2016.06.012 [doi]
AB  - SE36 antigen, derived from serine repeat antigen 5 (SERA5) of Plasmodium 
      falciparum, is a promising blood stage malaria vaccine candidate. Designated as 
      BK-SE36, the SE36 antigen was formulated with aluminum hydroxyl gel (AHG) and 
      produced under Good Manufacturing Practice (GMP) constraints. In a Phase Ib 
      clinical trial and follow-up study in Uganda, the risk for malaria symptoms was 
      reduced by 72% compared with the control group. Although promising, the number of 
      responders to the vaccine in 6-20years-olds was approximately 30% with the 
      majority in the younger cohort. This is in contrast to the phase Ia clinical 
      trial where response to the vaccine was 100% in Japanese malaria naive adults. A 
      consideration that can be of importance is the involvement of host genetic 
      factors that may influence the ability to mount an effective immune response to 
      vaccination as well as susceptibility to malaria infection. We, therefore, 
      analyzed allelic polymorphism of human leukocyte antigen (HLA)-DRB1 alleles using 
      sequence-based typing (SBT). In this study, DRB1 alleles did not influence 
      antibody response to BK-SE36 and the vaccinees susceptibility to clinical 
      malaria.
CI  - Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Tougan, Takahiro
AU  - Tougan T
AD  - Department of Molecular Protozoology, Research Institute for Microbial Diseases, 
      Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan. Electronic 
      address: ttougan@biken.osaka-u.ac.jp.
FAU - Ito, Kazuya
AU  - Ito K
AD  - Department of Public Health, Faculty of Medicine, Osaka City University, Osaka 
      545-8585, Japan; Sumida Hospital, Medical Co. Living Together Association (LTA) 
      Clinical Pharmacology Center, Tokyo 130-0021, Japan. Electronic address: 
      ito.kazuya@med.osaka-cu.ac.jp.
FAU - Palacpac, Nirianne Marie Q
AU  - Palacpac NM
AD  - Department of Molecular Protozoology, Research Institute for Microbial Diseases, 
      Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan. Electronic 
      address: nirian@biken.osaka-u.ac.jp.
FAU - Egwang, Thomas G
AU  - Egwang TG
AD  - Med Biotech Laboratories, Plot 4-6 Bell Close, Port Bell Road Luzira, Kampala, 
      Uganda. Electronic address: tgegwang@gmail.com.
FAU - Horii, Toshihiro
AU  - Horii T
AD  - Department of Molecular Protozoology, Research Institute for Microbial Diseases, 
      Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan. Electronic 
      address: horii@biken.osaka-u.ac.jp.
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
DEP - 20160623
PL  - Netherlands
TA  - Parasitol Int
JT  - Parasitology international
JID - 9708549
RN  - 0 (Antibodies, Protozoan)
RN  - 0 (Antigens, Protozoan)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Malaria Vaccines)
RN  - 0 (serine repeat antigen 5, Plasmodium falciparum)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Alleles
MH  - Antibodies, Protozoan/blood
MH  - Antigens, Protozoan/*immunology
MH  - Child
MH  - Female
MH  - HLA-DRB1 Chains/*genetics/immunology
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Malaria Vaccines/*immunology
MH  - Malaria, Falciparum/*immunology
MH  - Male
MH  - Plasmodium falciparum/*immunology
MH  - Uganda
MH  - Vaccination
MH  - Young Adult
OTO - NOTNLM
OT  - BK-SE36
OT  - Clinical malaria
OT  - HLA-DRB1
OT  - Immune tolerance
OT  - Malaria vaccine
EDAT- 2016/06/28 06:00
MHDA- 2017/03/14 06:00
CRDT- 2016/06/26 06:00
PHST- 2016/04/14 00:00 [received]
PHST- 2016/06/21 00:00 [revised]
PHST- 2016/06/21 00:00 [accepted]
PHST- 2016/06/26 06:00 [entrez]
PHST- 2016/06/28 06:00 [pubmed]
PHST- 2017/03/14 06:00 [medline]
AID - S1383-5769(16)30076-9 [pii]
AID - 10.1016/j.parint.2016.06.012 [doi]
PST - ppublish
SO  - Parasitol Int. 2016 Oct;65(5 Pt A):455-8. doi: 10.1016/j.parint.2016.06.012. Epub 
      2016 Jun 23.